Curated News
By: NewsRamp Editorial Staff
September 09, 2026
Quantum BioPharma's Lucid-MS Wins FDA Nod for Phase 2 MS Trial
TLDR
- Quantum BioPharma's Lucid-MS FDA clearance and new buy rating give investors an early edge in a first-in-class MS therapy.
- Lucid-MS is a patented compound that protects and repairs myelin, and it has received FDA clearance for a phase 2 clinical trial.
- Quantum BioPharma's Lucid-MS could transform multiple sclerosis care by targeting myelin repair instead of immune suppression, offering new hope.
- Quantum BioPharma's Lucid-MS aims to reverse myelin damage in MS, a novel approach that earned FDA clearance and analyst attention.
Impact - Why it Matters
This news matters because it represents a potential paradigm shift in multiple sclerosis treatment. Current therapies largely suppress the immune system, which can leave patients vulnerable to infections and other complications. Lucid-MS takes a different approach by aiming to protect and repair the myelin sheath—the protective covering of nerve fibers that is damaged in MS. If successful in clinical trials, this first-in-class candidate could offer a disease-modifying therapy that not only slows progression but potentially reverses disability. The FDA clearance for a Phase 2 trial is a critical step that most experimental drugs never achieve, and the new buy rating from analysts suggests that the financial community sees significant promise. For patients and investors alike, this milestone highlights Quantum BioPharma’s growing role in the neurodegenerative disease space and underscores the importance of continued investment in innovative biotech solutions.
Summary
Quantum BioPharma (NASDAQ: QNTM) has secured a prominent position in a BioMedWire editorial that examines its lead drug candidate, Lucid-MS, and its recent FDA clearance to begin a Phase 2 clinical trial. The editorial, titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” spotlights Lucid-MS as a patented, first-in-class therapy designed to protect and potentially repair the myelin sheath, rather than targeting the immune system like existing multiple sclerosis treatments. This regulatory milestone has also attracted a new buy rating from Wall Street analysts, signaling growing confidence in the company’s approach.
Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, which has shown in preclinical models the ability to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis. In addition to its MS program, Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, along with royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The news was disseminated through Quantum BioPharma (NASDAQ: QNTM), a specialized communications platform under the Dynamic Brand Portfolio @ IBN. BioMedWire provides access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. Investors can find the full press release at https://ibn.fm/dwwiP and stay updated via the company’s newsroom at https://ibn.fm/QNTM.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Wins FDA Nod for Phase 2 MS Trial
